Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — East White Plains, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in New York: - University of Rochester — Rochester, New York
- State University of New York Upstate Medical University — Syracuse, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in New York: - Investigative Site US059 — Lake Success, New York
- Investigative Site US031 — New York, New York
- Investigative Site US041 — New York, New York
- Investigative Site US004 — New York, New York
- Investigative Site US003 — New York, New York
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — Mineola, New York
- NYU Winthrop Hospital — Mineola, New York
- Local Institution - 0140 — New York, New York
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in New York: - Exelixis Clinical Site #59 — Buffalo, New York
- Exelixis Clinical Site #7 — New York, New York
- Exelixis Clinical Site #53 — Rochester, New York
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Sites in New York: - Albany Stratton VA Medical Center — Albany, New York
- Feinstein Institutes for Medical Research - Northwell Health — Manhasset, New York
- Columbia University Medical Center — New York, New York
- Montefiore Hospital — The Bronx, New York
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in New York: - NYU Long Island Mineola — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- White Plains Hospital Center for Cancer Care - Oncology — White Plains, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Sites in New York: - Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in New York: - Investigative Site — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in New York: - NYU Langone Health — New York, New York
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in New York: - Upstate Cancer Center at Oswego — Oswego, New York
- Stony Brook University Medical Center — Stony Brook, New York
- State University of New York Upstate Medical University — Syracuse, New York
- SUNY Upstate Medical Center-Community Campus — Syracuse, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in New York: - Ohio State University-Telemedicine — Albany, New York
- Ohio State University Telemedicine — Buffalo, New York
- Ohio State University-Telemedicine — New York, New York
- Ohio State University-Telemedicine — Syracuse, New York
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Mount Sinai Hospital — New York, New York
- NYP/Weill Cornell Medical Center — New York, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in New York: - Hematology Oncology Associates of Central New York — East Syracuse, New York
- Northwell Health Cancer Institute — Lake Success, New York
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in New York: - Memorial Sloan Kettering Cancer Center - Commack — Commack, New York
- Memorial Sloan Kettering Cancer Center at Westchester — Harrison, New York
- Northwell Health — Lake Success, New York
- NYU Langone Health — New York, New York
- Mount SInai Medical Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in New York: - Northwell Health / RJ Zuckerberg Cancer Center — Lake Success, New York
- Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center Main Campus — New York, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the sta…
Sponsor: Eli Lilly and Company
NCT ID: NCT04956640
Sites in New York: - NYU Langone Health- Long Island — Mineola, New York
- NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in New York: - Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Columbia University — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in New York: - Columbia University — New York, New York
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in New York: - Icahn School of Medicine at Mount Sinai - Oncology — New York, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus — New York, New York
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in New York: - NYU Langone Health — New York, New York
- Icahn School of Medicine At Mount Sinai Prime — New York, New York
- Clinical Research Alliance — Westbury, New York
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New York: - Weill Cornell Medicine, Cornell University (site 126) — New York, New York
Phase 2 Recruiting Industry
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04924075
Sites in New York: - Icahn School of Medicine at Mount Sinai ( Site 0123) — New York, New York
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in New York: - Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327) — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324) — New York, New York